Hana Michnová, A. Imramovský, Pratibha Magar, A. Čížek, J. Jampílek
{"title":"Antistaphylococcal activity of new salicylamide analogues","authors":"Hana Michnová, A. Imramovský, Pratibha Magar, A. Čížek, J. Jampílek","doi":"10.3390/ecmc2019-06344","DOIUrl":null,"url":null,"abstract":": Antimicrobial resistance is still a serious global threat. Staphylococcus aureus is a common cause of severe infections in health facilities and the community. People with methicillin-resistant S. aureus (MRSA) are estimated to be 64% more likely to die than people with a non-resistant form of the infection. For that reason, the research and development of new active compounds is really needed. Salicylamides are anti-infectious agents with a wide range of pharmacological effects, such us antiviral, antibacterial, antifungal and anthelminthic. Thus, derivatives of this group are very promising compounds. A series of newly synthesized complex salicylamide derivatives was tested for their antimicrobial effect against methicillin-resistant Staphylococcus aureus (MRSA). Staphylococcus aureus ATCC 29213 as a control and three isolates of MRSA were used. The activity was assessed by the evaluation of minimum inhibitory concentration. Using the microdilution method with subcultivation of aliquots, the minimum bactericidal concentration was determined too. Ciprofloxacin and ampicillin were used as standard antibacterial drugs. Four most promising compounds from the series were chosen and are demonstrated in this contribution.","PeriodicalId":312909,"journal":{"name":"Proceedings of 5th International Electronic Conference on Medicinal Chemistry","volume":"22 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Proceedings of 5th International Electronic Conference on Medicinal Chemistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/ecmc2019-06344","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
: Antimicrobial resistance is still a serious global threat. Staphylococcus aureus is a common cause of severe infections in health facilities and the community. People with methicillin-resistant S. aureus (MRSA) are estimated to be 64% more likely to die than people with a non-resistant form of the infection. For that reason, the research and development of new active compounds is really needed. Salicylamides are anti-infectious agents with a wide range of pharmacological effects, such us antiviral, antibacterial, antifungal and anthelminthic. Thus, derivatives of this group are very promising compounds. A series of newly synthesized complex salicylamide derivatives was tested for their antimicrobial effect against methicillin-resistant Staphylococcus aureus (MRSA). Staphylococcus aureus ATCC 29213 as a control and three isolates of MRSA were used. The activity was assessed by the evaluation of minimum inhibitory concentration. Using the microdilution method with subcultivation of aliquots, the minimum bactericidal concentration was determined too. Ciprofloxacin and ampicillin were used as standard antibacterial drugs. Four most promising compounds from the series were chosen and are demonstrated in this contribution.